Becton Dickinson & Co (BDX)
Health Care · Health Care Equipment · US stock · S&P 500 component
$191.75
▼ -2.01 (1.04%)
Fair valueOvervalued
$117 −39.2% to fair value
$58fair band $82–$152$175
Day's range
$190.21 – $195.99
52-week range
$124.47 – $195.99
About Becton Dickinson & Co
Becton Dickinson is a medical technology company that makes products used in hospitals, laboratories and clinics, including syringes, needles, catheters, infusion pumps, medication management systems and diagnostic tests. Its customers are hospitals and health systems, laboratories, pharmaceutical companies and other healthcare providers, many of which reorder disposable items regularly. The business operates through several medical technology units serving different parts of care.
Becton Dickinson earns revenue from recurring supplies of disposable devices, plus equipment, software and diagnostic products. Revenue is $23.2 billion over the last twelve months, growing at 5.0% a year across three years. The operating margin is 10.7%, and the business earns a profit of 5% on the capital invested in it. It carries net debt of 3.2 times EBITDA, and the dividend yield is 2.2%. On the site's X-Ray Score it receives 39 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $124.47 – $195.99Volume 1,412,700Daily, split-adjusted
Vitals
Market cap$52.8B
52-week range$124.47 – $195.99
Volume (last day)1,412,700
P/E (TTM)57.6
EBIT / EV yield3.6%
Free-cash-flow yield–
Dividend yield2.2%
Revenue (TTM)$23.3B
Net income (TTM)$941M
Operating margin10.7%
Return on capital5.4%
Debt incl. leases$16.8B
Cash & securities$708M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$117model spread $110 – $123
Overvalued
−39.2% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $192
Undervalued < $82Fair $82 – $152Overvalued > $152
10-year DCF (market-scaled)
$88
Peer multiples
$127
Earnings power floor (not blended)
$41
Fundamentals-adjusted multiple
$135
Growth the price implies
18.8%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, priced high
Our models put fair value below today's price, so a lot of good news may already be in the price. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
31/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield3.6%
Fair value vs price0.6×
Growth
Weak
39/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)5.0%
EPS growth (3y)-0.3%
Growth consistency80%
Profitability
Weak
38/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital5.4%
Operating margin10.7%
Gross profitability21.5%
Financial health
Weak
42/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score8 / 9
Net debt / EBITDA3.2×
Interest cover4.2×
Dividends
Fair
59/100
Dividend is typical for its sector.
See the numbers →
Dividend yield2.2%
Dividend growth3.4%
Quarterly results: last 6 quarters
-11.2%
Mar '25
-5.3%
Jun '25
+52.7%
Sep '25
+1.6%
Dec '25
+5.2%
Mar '26
+5.4%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $5.0B, diluted EPS $1.37.
Compare with peers
RMD Resmed Inc73 DXCM Dexcom Inc71 PODD Insulet Corp69 IDXX Idexx Laboratories Inc67Other Health Care Equipment companies by X-Ray Score.
Fundamentals checklist
● 1 Good · ● 2 Average · ● 10 BadCash quality
Risk models
Altman Z''Bad
Piotroski F-ScoreGood
Growth
EPS growth (3y)Bad
Revenue growth (3y)Average
Growth consistencyBad
Balance sheet
Current ratioBad
Net debt / EBITDABad
Interest coverBad
Valuation
Fair value vs priceBad
EBIT / EV yieldAverage
Profitability
Return on invested capitalBad
Operating marginBad
Gross profitabilityBad
Each check is graded against the company's sector, not a fixed number. Checklist score 29/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $19.1B | $18.9B | $19.4B | $20.2B | $21.8B |
| Operating income | $2.3B | $2.3B | $2.1B | $2.4B | $2.6B |
| Net income | $2.1B | $1.8B | $1.5B | $1.7B | $1.7B |
| Operating cash flow | $4.6B | – | – | – | – |
| Operating margin | 11.8% | 12.1% | 10.9% | 11.9% | 11.8% |
| Free cash flow | $3.5B | – | – | – | – |
| Diluted EPS | $6.85 | $5.88 | $4.94 | $5.86 | $5.82 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 3 neutral · 1 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 185.8 | Bullish |
| EMA 10 | 187.2 | Bullish |
| SMA 20 | 183.4 | Bullish |
| EMA 20 | 184.8 | Bullish |
| SMA 50 | 183.4 | Bullish |
| EMA 50 | 180.0 | Bullish |
| SMA 100 | 168.0 | Bullish |
| EMA 100 | 172.6 | Bullish |
| SMA 200 | 162.4 | Bullish |
| EMA 200 | 165.1 | Bullish |
Oscillators (daily)
| RSI (14) | 63.91 | Neutral |
| MACD (12, 26) | 2.56 | Bullish |
| Momentum (12) | 7.12 | Bullish |
| Stochastic %K (14) | 79.09 | Neutral |
| Williams %R (14) | -20.91 | Neutral |
| CCI (20) | 193.1 | Bearish |
Pivot points (classic, last session)
S3 183.5 | S2 186.9 | S1 189.3 | Pivot 192.7 | R1 195.1 | R2 198.4 | R3 200.9 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
4.20 USD
Yield on today's price
2.19%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 9 Sep 2026 | 1.0500 |
| 9 Jun 2026 | 1.0500 |
| 10 Mar 2026 | 1.0500 |
| 8 Dec 2025 | 1.0500 |
| 8 Sep 2025 | 1.0400 |
| 9 Jun 2025 | 1.0400 |
| 10 Mar 2025 | 1.0400 |
| 9 Dec 2024 | 1.0400 |
| 9 Sep 2024 | 0.9500 |
| 10 Jun 2024 | 0.9500 |
| 7 Mar 2024 | 0.9500 |
| 7 Dec 2023 | 0.9500 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
BDX SEC filings
6 Aug 2026
8-KSEC EDGAR
Results of operations
6 Aug 2026
10-QSEC EDGAR
Quarterly report
22 Jul 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
29 May 2026
8-KSEC EDGAR
Regulation FD disclosure
20 May 2026
8-KSEC EDGAR
Entered a material agreement
12 May 2026
8-KSEC EDGAR
Other events
7 May 2026
8-KSEC EDGAR
Results of operations
7 May 2026
10-QSEC EDGAR
Quarterly report
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.